Latest News

At the European Hematology Association Congress, researchers presented on novel treatments and combinations for newly diagnosed multiple myeloma, relapsed disease, and smoldering myeloma.

A phase 3 trial of givastomig is expected to begin as early as the fourth quarter of 2026.

A retrospective analysis shows strong outcomes with CAR T-cell therapy in real-world patients with multiple myeloma, Doris K. Hansen, MD, explains.

During a live event, Brittany Siontis, MD, discussed treatment strategies for a patient with a progressive abdominal desmoid tumor.

During a live event, Bruna Pellini, MD, and participants discussed frontline treatment selection for patients with ROS1-positive advanced non–small cell lung cancer, including how evolving efficacy and tolerability data are shifting practice toward newer-generation TKIs.

The FDA set a target date of April 14, 2027 to review ozekibart as targeted treatment for chondrosarcoma.

The phase 3 trial showed benefit with talquetamab/daratumumab with or without pomalidomide as early as the second line in myeloma.

Topline data show no overall survival advantage for lurbinectedin monotherapy or combination therapy over investigators' choice in second-line metastatic small cell lung cancer; drug's first-line maintenance approval remains intact.

The FDA concurrently cleared the VENTANA PTEN (SP218) RxDx assay as a companion diagnostic to identify eligible patients.

The adjuvant approval of the belzutifan combination is supported by the LITESPARK-022 trial.

FBEM conditioning in ALL alloHSCT yields 92.1% 2-year OS and 14.3% relapse rate, with 0% 100-day NRM and manageable GVHD in 203 patients.

Real-world data show tarlatamab achieved 27.7% ORR and manageable toxicity in heavily pretreated patients with ES-SCLC with brain metastases at a single academic center.

In vivo anti-BCMA CAR T infusion shows favorable efficacy and safety with some patients beyond 9 months free of progression.

The supplemental biologics license application is supported by the phase 3 ATOMIC trial.

Alembic receives tentative FDA approval for generic larotrectinib capsules, a TRK inhibitor for NTRK fusion–positive solid tumors, with potential 180-day exclusivity.

FDA granted RMAT designation to lasme-cel, a CD22-targeting allogeneic CAR-T, for R/R B-ALL, the first such therapy in a pivotal trial for this indication.

The new designation, which adds to an existing orphan drug designation for the same indication, allows for a priority review voucher and other development incentives.

During a live event, Sikander Ailawadhi, MD, and participants discussed sequencing and bridging therapy selection for patients with early relapsed multiple myeloma who are candidates for CAR T-cell therapy.

Off-the-shelf CD19 CAR T azer-cel earns FDA Fast Track after early trials show striking responses in refractory CLL/SLL and marginal zone lymphoma.

Merck and Gilead discontinue KEYNOTE-D46/EVOKE-03 after combination fails to demonstrate statistically significant progression-free survival benefit over pembrolizumab monotherapy

The phase 3 WU-KONG28 trial found that sunvozertinib decreased disease progression risk by 35% and nearly doubled response rates vs platinum-based chemotherapy in treatment-naive patients with NSCLC harboring EGFR exon 20 insertions.

Experts debate first-line poor-risk metastatic ccRCC: ICI‑TKI for rapid control vs dual ICI for durable benefit, guided by updated NCCN 2026.

Updated data from ASCO 2026 highlight advances in TNBC and HR+ breast cancer, including novel agents, biomarker strategies, and GLP-1 RA findings.

The combo did not, however, meet the coprimary end point of absolute change in total symptom score.

During a live event, Syed Abbas Ali, MBBS, and participants discussed current referral practices for second-line CAR T-cell therapy in multiple myeloma.

Switching early to camizestrant with a CDK4/6 inhibitor after ESR1 mutation detection extends progression-free outcomes in ER-positive breast cancer, despite FDA debate.

Phase 3 data show giredestrant plus palbociclib misses significant PFS gain vs letrozole, with similar safety, guiding future trials.

Timothy Hembree, DO, PhD, discusses how patients and physicians have benefited from an AI-supported virtual care system implemented at Moffitt Cancer Center.

A sneak peek at the heme-onc abstracts at EHA 2026: CLL triplets, frontline menin inhibition, earlier myeloma bispecifics, and post‑JAK myelofibrosis combos poised to shift care.

LOTIS-5 finds loncastuximab tesirine plus rituximab improves PFS and response rates in relapsed/refractory DLBCL vs R-GemOx.

A first-in-human trial of the antibody-drug conjugate is planned for later this year.